Cytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.74 million.

Q1 2018 operating cash burn was $4.1 million, compared to $4.8 million for Q1 2017.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.